AMR Centre nominates MBL inhibitor

摘要

The AMR Centre has nominated a preclinical candidate molecule for its programme to overcome resistance mechanisms in bacteria.The MB1.inhibitor,which restores the function of beta-lactam antibiotics,will progress to clinical trials in late 2020 after another 12 months of research to ensure it is safe for use in humans.AMRC's Executive Director,Dr Peter Jackson said:”Our MBL inhibitor will be one of the first and,we hope,most effective broad-spectrum therapies against die emerging class of superbugs coming out of India and China.”